Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ren Shen Yang Rong Tang for Microinflammation in Hemodialysis Patients
NCT02053740Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2013
- Primary completion
- Aug 2013
- Countries
- 1
- Sponsor
- Tri-Service General Hospital
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of Ren Shen Yang Rong Tang (2 arms), sponsored by Tri-Service General Hospital. Primary endpoint: Inflammatory markers at 6 months. Started Jan 2013; status: completed.
02
Design
2 arms- Study design
- Open-label
R-S-Y-R-T Group
Ren Shen Yang Rong Tang (500 mg 3 times per day) + Routine western medicine
Control Group
Routine western medicine alone
03
Who it enrols
Adult patients (18+) on maintenance hemodialysis for at least 3 months. Excludes patients with malignancy, acute infection, gastrointestinal bleeding, or pregnancy.
04
Endpoints
Primary
Inflammatory markers
Secondary
Quality of Life
Beyond the preview
Go deeper on NCT02053740.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053740.